Colchicine Savings Program to End 12/31/23

Mitigare® True Blue Savings Program Ends This Month West-Ward Pharmaceuticals Inc. (now Hikma Pharmaceuticals USA Inc.) changed the Colchicine market in 2016 by introducing Mitigare® (Colchicine) 0.6mg Capsules for prophylaxis of gout flares in adults.1 Soon after…

Drug Interactions With Colchicine: Learn Which Medications Interact With Your Gout Drug

Did you know that over 20 percent of adults 40 and older take five or more prescription drugs each day?1 If you take more than one medication, you could be at risk for a drug interaction.2 Read on…

3 Reasons to Choose the Colchicine Capsule

Many people take colchicine to help prevent the sudden, painful episodes known as gout flares (also known as gout attacks).1,2 The drug is available in capsule, tablet and liquid formulations.3 Some people may find that Colchicine Capsules have

What Not to Do During a Gout Flare

According to the results of a survey conducted by the Gout Education Society, one in five people with gout believe that the pain of a gout flare is worse than any other pain imaginable.1 (If you’ve ever experienced a…

Take Your Gout Medicine as Directed

If you take medicine for gout and occasionally miss a dose, you’re not alone.1 Medication nonadherence (failure to follow through with treatment) occurs in as many as 40 to 50 percent of patients who take medicine for a chronic…

Do I Need Gout Medicine?

If you have gout, your first flare probably came as quite a surprise.1 Maybe you went to sleep feeling fine, only to be awakened in the middle of the night by a big toe that was burning hot,

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.
  • Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.
  • Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.
  • Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.
  • Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.
  • The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis has not been studied.

Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

For Full Prescribing Information please CLICK HERE and for Medication Guide CLICK HERE.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4.